Sex differences and genomics in autoimmune diseases

Journal of Autoimmunity

Volumn 38, Issue 2-3, 2012, Pages

  Amur, Shashi ^a   Parekh, Ameeta ^a   Mummaneni, Padmaja ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Autoimmune; Autoimmunity; Gender; Genetics; Genomics; Sex

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; FINGOLIMOD; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOXANTRONE; NATALIZUMAB; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; STEROID;

ADDISON DISEASE; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; CELIAC DISEASE; CHRONIC ACTIVE HEPATITIS; CLINICAL TRIAL (TOPIC); DERMATOMYOSITIS; DISEASE PREDISPOSITION; DIZYGOTIC TWINS; DNA METHYLATION; DRUG SCREENING; ENTERITIS; ENVIRONMENTAL FACTOR; ETHNICITY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOMICS; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HEREDITY; HISTONE MODIFICATION; HUMAN; HYPOTHYROIDISM; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICATION THERAPY MANAGEMENT; MONOSOMY X; MONOZYGOTIC TWINS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PERNICIOUS ANEMIA; POLYMYOSITIS; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SJOEGREN SYNDROME; STEROID THERAPY; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; THYROID FUNCTION; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE; TWIN CONCORDANCE; UVEITIS; VITILIGO; X CHROMOSOME; X CHROMOSOME INACTIVATION;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; CHROMOSOMES, HUMAN, X; FEMALE; GENOMICS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PREVALENCE; SEX FACTORS;

EID: 84858753127     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.12.001     Document Type: Article

References (139)

1. Gleicher N., Barad D.H. Gender as risk factor for autoimmune diseases. J Autoimmun 2007, 28:1-6.
2. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84:223-243.
3. Fairweather D., Frisancho-Kiss S., Rose N.R. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008, 173:600-609.
4. Libert C., Dejager L., Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol 2010, 10:594-604.
5. Gonzalez R., Gomis-Tena J., Corrias A., Ferrero J.M., Rodriguez B., Saiz J. Sex and age related differences in drug induced QT prolongation by dofetilide under reduced repolarization reserve in simulated ventricular cells. Conf Proc IEEE Eng Med Biol Soc 2010, 2010:3245-3248.
6. Rubtsov A.V., Rubtsova K., Kappler J.W., Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9:494-498.
7. Kivity S., Ehrenfeld M. Can we explain the higher prevalence of autoimmune disease in women?. Expert Rev Clin Immunol 2010, 6:691-694.
8. UNSW Embryology Abnormal development-Thalidomide. http://embryology.med.unsw.edu.au/Defect/page5i.htm.
9. Pinn V.W. The role of the NIH's Office of research on Women's health. Acad Med 1994, 69:698-702.
10. Dept of Health and Human Services: Women's health Report of the Public Health Service Task Force on Women's Health Issues Public Health Report; DHHS Publication no 85-50206 J; 1985, p. 73-106.
11. Seminar on women in clinical trials of FDA-regulated products: who Participates and who Decides?. Food Drug Law J 1993, 48:61-226.
12. McCarthy C. Historical Background of clinical trials involving women and minorities. Academic Medicine 1994, 69:695-698.
13. National Institutes of Health Revitalization Act of 1993 http://orwh.od.nih.gov/about/acrwh_news/Revitalization%20%20PDF%206-12-08.pdf.
14. Gender Guideline Study and Evaluation of gender differences in the clinical Evaluation of drugs 1993, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072044.pdf.
15. U.S. Department of Health and Human Services, Food and Drug Administration. Investigational new drug applications; Amendment to clinical hold regulations for products intended for life-threatening diseases and conditions. Fed Regist 2000, 65:34963-34971. http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm120264.htm.
16. Guidances (Drugs). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
17. Poon R., Khanijow K., Umarjee S., Fadiran E., Yu M., Zhang L., et al. A participation of women and sex analyses in late phase clinical trials of New molecular Entity (NME) drugs and biologics approved by the FDA in 2007-2009. Drug information association 2011 47th annual meeting June 19-23, 2011, Chicago, IL.
18. Copeland V, Sahajwalla, C, Parekh, A. Sex-Differences in exposure for FDA approved New molecular Entities (NMEs) 2007-2010: exposure based dosing in subgroup populations. American Association of Pharmaceutical Scientists annual meeting, Oct 23-27, 2011, Washington DC. http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm201358.htm.
19. Women's health research: progress, Pitfalls and Promise. (Report from committee on Women's health research, Institute of medicine) committee on Women's health research, Institute of Medicine; http://www.iom.edu/%7E/media/Files/Report%20Files/2010/Womens-Health-Research-Progress-Pitfalls-and-Promise/Womens%20Health%20Research%202010%20Report%20Brief.pdf.
20. Invernizzi P. Future directions in genetic for autoimmune diseases. J Autoimmun 2009, 33:1-2.
21. Bias W.B., Reveille J.D., Beaty T.H., Meyers D.A., Arnett F.C. Evidence that autoimmunity in man is a Mendelian dominant trait. Am J Hum Genet 1986, 39:584-602.
22. Wandstrat A., Wakeland E. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol 2001, 2:802-809.
23. Muers M. Complex disease: ups and downs at the MHC. Nat Rev Genet 2011, 12:456-457.
24. Invernizzi P., Gershwin M.E. The genetics of human autoimmune disease. J Autoimmun 2009, 33:290-299.
25. Fernando M.M.A., Stevens C.R., Walsh E.C., De Jager P.L., Goyette P., Plenge R.M., et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. Plos Genet 2008, 4(4):e1000024.
26. Boberg K.M. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002, 6:635-647.
27. Undlien D.E., Friede T., Rammensee H.G., Joner G., Dahl-Jorgensen K., Sovik O., et al. HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 1997, 46:143-149.
28. Czaja A.J., Strettell M.D.J., Thomson L.J., Santrach P.J., Moore S.B., Donaldson P.T., et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997, 25:317-323.
29. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004, 36:337-338.
30. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75:330-337.
31. Lleo A., Battezzati P.M., Selmi C., Gershwin M.E., Podda M. is autoimmunity a matter of sex?. Autoimmun Rev 2008, 7:626-630.
32. Ozcelik T. X chromosome inactivation and female predisposition to autoimmunity. Clin Rev Allerg Immu 2008, 34:348-351.
33. Selmi C. The X in sex: how autoimmune diseases revolve around sex chromosomes. Best Pract Res Cl Rh 2008, 22:913-922.
34. Ozbalkan Z., Bagislar S., Kiraz S., Akyerli C.B., Ozer H.T., Yavuz S., et al. Skewed X chromosome inactivation in blood cells of women with scleroderma. Arthritis Rheum 2005, 52:1564-1570.
35. Davis C.J., Davison R.M., Payne N.N., Rodeck C.H., Conway G.S. Female sex preponderance for idiopathic familial premature ovarian failure suggests an X chromosome defect. Hum Reprod 2000, 15:2418-2422.
36. Sybert V.P., McCauley E. Turner's syndrome. New Engl J Med 2004, 351:1227-1238.
37. Valiaho L., Riikonen P., Vihinen M. Novel immunodeficiency data servers. Immunol Rev 2000, 178:177-185.
38. Strickland F.M., Richardson B.C. Epigenetics in human autoimmunity. Epigenetics in autoimmunity - DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 2008, 41:278-286.
39. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010, 34:J207-J219.
40. Jimenez S., Cervera R., Font J., Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allerg Immu 2003, 25:3-11.
41. Johnson A.E., Gordon C., Palmer R.G., Bacon P.A. The prevalence and incidence of systemic lupus-erythematosus in Birmingham, England - Relationship to ethnicity and Country of Birth. Arthritis Rheum 1995, 38:551-558.
42. McAlindon T. Update on the epidemiology of systemic lupus erythematosus: new spins on old ideas. Curr Opin Rheumatol 2000, 12:104-112.
43. Ansar AS Talal N Importance of sex hormones in systemic lupus Erythematosus 1993, Lea and Febiger, Philadelphia.
44. Choubey D., Panchanathan R., Duan X., Liu H. Emerging roles for the interferon-Inducible p200-family proteins in sex bias in systemic lupus erythematosus. Journal of interferon & cytokine research 2011, 31(12):893-906.
45. Rider V., Abdou N.I. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int Immunopharmacol 2001, 1:1009-1024.
46. Sestak A.L., Nath S.K., Sawalha A.H., Harley J.B. Current status of lupus genetics. Arthritis Res Ther 2007, 9:210-218.
47. Mageed R.A., Prud'homme G.J. Immunopathology and the gene therapy of lupus. Gene Ther 2003, 10:861-874.
48. Harley I.T.W., Kaufman K.M., Langefeld C.D., Harley J.B., Kelly J.A. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009, 10:285-290.
49. Crow M.K., Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003, 5:279-287.
50. Arasappan D., Tong W., Mummaneni P., Fang H., Amur S. Meta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells. BMC Med 2011, 9:65-74.
51. Sherman SI TR Thyroid disorders 2008, McGraw-Hill Medical, New York, NY. 7 ed.
52. Brent G.A. Graves' disease. New Engl J Med 2008, 359:1407-1409.
53. Streetman D.D., Khanderia U. Diagnosis and treatment of Graves disease. Ann Pharmacother 2003, 37:1100-1109.
54. Dasilva J.A.P. Sex-Hormones, Glucocorticoids and autoimmunity - Facts and Hypotheses. Ann Rheum Dis 1995, 54:6-16.
55. Allahabadia A., Daykin J., Holder R.L., Sheppard M.C., Gough S.C., Franklyn J.A. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J clinical endocrinology Metabolism 2000, 85:1038-1042.
56. Villanueva R., Greenberg D.A., Davies T.F., Tomer Y. Sibling recurrence risk in autoimmune thyroid disease. Thyroid: Official Journal Am Thyroid Assoc 2003, 13:761-764.
57. Hall R., Dingle P.R., Roberts D.F. Thyroid antibodies: a study of first degree relatives. Clin Genetics 1972, 3:319-324.
58. Brix T.H., Christensen K., Holm N.V., Harvald B., Hegedus L. A population-based study of Graves' disease in Danish twins. Clin Endocrinology 1998, 48:397-400.
59. Tomer Y. Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid: Official Journal Am Thyroid Assoc 2010, 20:715-725.
60. Brand O.J., Gough S.C. Genetics of thyroid autoimmunity and the role of the TSHR. Mol Cell Endocrinol 2010, 322:135-143.
61. Burton P.R., Clayton D.G., Cardon L.R., Craddock N., Deloukas P., Duncanson A., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007, 39:1329-1337.
62. Stalberg P., Svensson A., Hessman O., Akerstrom G., Hellman P. Surgical treatment of Graves' disease: evidence-based approach. World J Surg 2008, 32:1269-1277.
63. Hegedus L. Treatment of Graves' hyperthyroidism: evidence-based and emerging Modalities. Endocrin Metab Clin 2009, 38:355-371.
64. Cooper D.S. Drug therapy: antithyroid drugs. New Engl J Med 2005, 352:905-917.
65. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361:496-509.
66. Neimann A.L., Porter S.B., Gelfand J.M. The epidemiology of psoriasis. Expert Rev Clin Dermatol 2006, 1:63-75.
67. Duffin K.C., Krueger G.G. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol 2009, 129:827-833.
68. Hebert H.L., Ali F.R., Bowes J., Griffiths C.E., Barton A., Warren R.B. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 2011, [Epub ahead of print]. 10.1111/j.1365-2133.2011.10712.x.
69. Koczan D., Guthke R., Thiesen H.J., Ibrahim S.M., Kundt G., Krentz H., et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005, 15:251-257.
70. Quekennorn-Trinquet V., Fogel P., Aldana-Jammayrac O., Ancian P., Demarchez M., Rossio P., et al. Gene expression profiles in psoriasis:analysis of impact of body site location and clinical severity. Br J Dermatol 2005, 152:489-504.
71. Liu Y., Luo W., Chen S. Comparison of gene expression profiles reveals aberrant expression of FOXO1, Aurora A/B and EZH2 in lesional psoriatic skins. Mol Biol Rep 2011, 38:4219-4224.
72. Bartlett B.L., Tyring S.K. Ustekinumab for chronic plaque psoriasis. Lancet 2008, 371:1639-1640.
73. Oksenberg J.R., Barcellos L.F. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun 2005, 6:375-387.
74. Sellner J., Kraus J., Awad A., Milo R., Hemmer B., Stuve O. The increasing incidence and prevalence of female multiple sclerosis-A critical analysis of potential environmental factors. Autoimmun Rev 2011, 10:495-502.
75. Greer J.M., McCombe P.A. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunology 2011, 234:7-18.
76. Simpson S., Blizzard L., Otahal P., Van der Mei I., Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosur Ps 2011, 82:1132-1141.
77. Miller A.E. Multiple sclerosis: where will we be in 2020?. Mt Sinai J Med 2011, 78:268-279.
78. El-Etr M., Ghoumari A., Sitruk-Ware R., Schumacher M. Hormonal influences in multiple sclerosis: new therapeutic benefits for steroids. Maturitas 2011, 68:47-51.
79. Baranzini S.E. Revealing the genetic basis of multiple sclerosis: are we there yet?. Curr Opin Genet Dev 2011, 21:317-324.
80. Johnson B.A., Wang J., Taylor E.M., Caillier S.J., Herbert J., Khan O.A., et al. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun 2010, 11:343-350.
81. McElroy J.P., Isobe N., Gourraud P.A., Caillier S.J., Matsushita T., Kohriyama T., et al. SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients. Genes Immun 2011, 12:523-530.
82. Dutta R., Trapp B.D. Gene expression profiling in multiple sclerosis brain. Neurobiol Dis 2012, 45(1):108-114.
83. Achiron A., Gurevich M. Peripheral blood gene expression signature mirrors central nervous system disease: the model of multiple sclerosis. Autoimmun Rev 2006, 5:517-522.
84. Comabella M., Lunemann J.D., Rio J., Sanchez A., Lopez C., Julia E., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.
85. Glocker M.O., Guthke R., Kekow J., Thiesen H.-J. Rheumatoid Arthritis, a complex multifactorial disease: on the way toward individualized medicine. Med Research Reviews 2005, 26:63-87.
86. Oliver J.E., Silman A.J. Why are women predisposed to autoimmune rheumatic diseases?. Arthritis Res Ther 2009, 11:252.
87. Silman A.J., Macgregor A.J., Thomson W., Holligan S., Carthy D., Farhan A., et al. Twin concordance rates for rheumatoid-arthritis - Results from a Nationwide study. Brit J Rheumatol 1993, 32:903-907.
88. de Vries R. Genetics of rheumatoid arthritis: time for a change!. Curr Opin Rheumatol 2011, 23:227-232.
89. Rioux J.D., Goyette P., Vyse T.J., Hammarstrom L., Fernando M.M.A., Green T., et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. P Natl Acad Sci USA 2009, 106:18680-18685.
90. Kunz M., Ibrahim S.M. Non-major histocompatibility complex rheumatoid arthritis susceptibility genes. Crit Rev Immunol 2011, 31:99-114.
91. Plenge R.M. Recent progress in rheumatoid arthritis genetics: one step towards improved patient care. Curr Opin Rheumatol 2009, 21:262-271.
92. Goetz I., Carter G.C., Lucero M., Zarotsky V., Alatorre C.I., Cantrell R.A., et al. Review of treatment response in rheumatoid arthritis: assessment of heterogeneity. Curr Med Res Opin 2011, 27:697-711.
93. Junker A., Hohlfeld R., Meinl E. The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol 2011, 7:56-59.
94. Tufekci K.U., Oner M.G., Genc S., Genc K. MicroRNAs and multiple sclerosis. Autoimmune Dis 2011, 10.4061/2011/807426.
95. Zhou X., Tan F.K., Xiong M., Arnett F.C., Feghali-Bostwick C.A. Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum 2005, 52:3305-3314.
96. Icen M., Crowson C.S., McEvoy M.T., Dann F.J., Gabriel S.E., Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009, 60:394-401.
97. Carter E.T., McKenna C.H., Brian D.D., Kurland L.T. Epidemiology of ankylosing spondylitis in Rochester, Minnesota, 1935-1973. Arthritis Rheum 1979, 22:365-370.
98. Sejvar J.J., Baughman A.L., Wise M., Morgan O.W. Population incidence of guillain-barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011, 36:123-133.
99. Spiller R.C. Irritable bowel syndrome: gender, infection, lifestyle or what else?. Dig Dis 2011, 29:215-221.
100. Ringold D.A., Nicoloff J.T., Kesler M., Davis H., Hamilton A., Mack T. Further evidence for a strong genetic influence on the development of autoimmune thyroid disease: the California twin study. Thyroid 2002, 12:647-653.
101. Hemminki K., Li X., Sundquist J., Sundquist K. Familial association between type 1 diabetes and other autoimmune and related diseases. Diabetologia 2009, 52:1820-1828.
102. Larsen C.E., Alper C.A. The genetics of HLA-associated disease. Curr Opin Immunol 2004, 16:660-667.
103. Ramanujam R., Pirskanen R., Ramanujam S., Hammarstrom L. Utilizing twins concordance rates to infer the predisposition to myasthenia gravis. Twin Res Hum Genet 2011, 14:129-136.
104. Thomas E., Hay E.M., Hajeer A., Silman A.J. Sjogren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 1998, 37:1069-1076.
105. Edwards C.N., Griffith S.G., Hennis A.J., Hambleton I.R. Inflammatory bowel disease: incidence, prevalence, and disease characteristics in Barbados, West Indies. Inflamm Bowel Dis 2008, 14:1419-1424.
106. Alkhateeb A., Fain P.R., Thody A., Bennett D.C., Spritz R.A. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. Pigm Cell Res 2003, 16:208-214.
107. Asumalahti K., Laitinen T., Itkonen-Vatjus R., Lokki M.L., Suomela S., Snellman E., et al. A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum Mol Genet 2000, 9:1533-1542.
108. Gough S.C., Simmonds M.J. The HLA region and autoimmune disease: associations and mechanisms of Action. Curr Genomics 2007, 8:453-465.
109. Wiebolt J., Koeleman B.P., van Haeften T.W. Endocrine autoimmune disease: genetics become complex. Eur J Clin Invest 2010, 40:1144-1155.
110. Hirschfield G.M., Liu X., Xu C., Lu Y., Xie G., Gu X., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009, 360:2544-2555.
111. Duarte-Rey C., Pardo A.L., Rodriguez-Velosa Y., Mantilla R.D., Anaya J.M., Rojas-Villarraga A. HLA class II association with autoimmune hepatitis in Latin America: a meta-analysis. Autoimmun Rev 2009, 8:325-331.
112. Brenner W., Gschnait F., Mayr W.R. HLA B13, B17, B37 and Cw6 in psoriasis vulgaris: association with the age of onset. Arch Dermatol Res 1978, 262:337-339.
113. Feehally J., Farrall M., Boland A., Gale D.P., Gut I., Heath S., et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010, 21:1791-1797.
114. Ungar B., Mathews J.D., Tait B.D., Cowling D.C. Hla-Dr patterns in Pernicious-Anemia. Brit Med J 1981, 282:768-770.
115. Phelps R.G., Rees A.J. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999, 56:1638-1653.
116. Spritz R.A. Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol 2011, 10.1038/jid.2011.321.
117. Azuma Y., Sakurami T., Ueno Y., Ohishi M., Saji H., Terasaki P.I., et al. HLA-DR antigens in Japanese with Hashimoto's thyroiditis and Graves' disease. Endocrinol Jpn 1982, 29:423-427.
118. Miyamori H., Kato Y., Kobayashi K., Hattori N. HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. Digestion 1983, 26:213-217.
119. Selmi C., Torok N.J., Affronti A., Gershwin M.E. Genomic variants associated with primary biliary cirrhosis. Genome Med 2010, 2:5.
120. Pessach I.M. The Relationship of X-Linked primary immune deficiencies and autoimmunity. Curr Allergy Asthm R 2010, 10:311-319.
121. Hernandez-Molina G., Svyryd Y., Sanchez-Guerrero J., Mutchinick O.M. The role of the X chromosome in immunity and autoimmunity. Autoimmun Rev 2007, 6:218-222.
122. Etzioni A. Immune deficiency and autoimmunity. Autoimmun Rev 2003, 2:364-369.
123. Simmonds M.J., Heward J.M., Barrett J.C., Franklyn J.A., Gough S.C. Association of the BTNL2 rs2076530 single nucleotide polymorphism with Graves' disease appears to be secondary to DRB1 exon 2 position beta74. Clin Endocrinol (Oxf) 2006, 65:429-432.
124. Velaga M.R., Wilson V., Jennings C.E., Owen C.J., Herington S., Donaldson P.T., et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 2004, 89:5862-5865.
125. Liu Y., Helms C., Liao W., Zaba L.C., Duan S., Gardner J., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008, 4:e1000041.
126. Mero I.L., Lorentzen A.R., Ban M., Smestad C., Celius E.G., Aarseth J.H., et al. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur J Hum Genet 2010, 18:502-504.
127. Alcina A., Vandenbroeck K., Otaegui D., Saiz A., Gonzalez J.R., Fernandez O., et al. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes Immun 2010, 11:439-445.
128. Bowes J., Lawrence R., Eyre S., Panoutsopoulou K., Orozco G., Elliott K.S., et al. Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. Hum Genet 2010, 128:627-633.
129. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977-986.
130. Raychaudhuri S., Remmers E.F., Lee A.T., Hackett R., Guiducci C., Burtt N.P., et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008, 40:1216-1223.
131. Suarez-Gestal M., Calaza M., Endreffy E., Pullmann R., Ordi-Ros J., Sebastiani G.D., et al. Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. Arthritis Res Ther 2009, 11:R69.
132. Eleftherohorinou H., Hoggart C.J., Wright V.J., Levin M., Coin L.J.M. Pathway-driven gene stability selection of two rheumatoid arthritis GWAS identifies and validates new susceptibility genes in receptor mediated signalling pathways. Hum Mol Genet 2011, 20:3494-3506.
133. The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
134. Jarvinen T.M., Hellquist A., Zucchelli M., Koskenmies S., Panelius J., Hasan T., et al. Replication of genome-wide association study identified systemic lupus erythematosus susceptibility genes affirms B-cell receptor pathway signalling and strengthens the role of IRF5 in disease susceptibility in a Northern European population. Rheumatology (Oxford) 2011, 10.1093/rheumatology/ker263.
135. Burkhardt J., Petit-Teixeira E., Teixeira V.H., Kirsten H., Garnier S., Ruehle S., et al. Association of the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis. J Rheumatol 2009, 36:2149-2157.
136. Dieude P., Bouaziz M., Guedj M., Riemekasten G., Airo P., Muller M., et al. Evidence for the contribution of the X chromosome to Systemic Sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum 2011, 63(12):3979-3987.
137. Invernizzi P., Pasini S., Podda M. X chromosome in autoimmune diseases. Expert Rev Clin Immunol 2008, 4:591-597.
138. Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: Plausible mechanisms for the female predominance of autoimmunity. J Autoimmun, 2011.
139. Pessach I.M. The relationship of x-linked primary immune deficiencies and autoimmunity. Curr Allergy Asthma Rep 2010, 10:311-319.